The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.
Eli Lilly substantively modified nine risk factors between the 2024 and 2025 filings while maintaining all existing risk categories with no additions or removals. The most significant revisions addressed geopolitical tensions and global disruptions, manufacturing and supply chain resilience, and litigation exposures related to product pricing and commercialization. These modifications suggest Lilly strengthened its disclosure of evolving operational challenges in geopolitics, supply chain management, and legal compliance without fundamentally restructuring its risk disclosure framework.
Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.
🟡 Modified
•Uneven economic growth or downturns or international trade and other global disruptions, geopolitical tensions, or disputes could adversely affect our business and operating results.
🔒
🟡 Modified
•Manufacturing, quality, or supply chain difficulties, disruptions, or shortages could lead to product supply problems.
🔒
🟡 Modified
•We are party to litigation and investigations related to our products, how we price or commercialize our products, and other aspects of our business, which could adversely affect our business, and we are self-insured for such matters.
🔒
🟡 Modified
•Changes in foreign currency rates, interest rate risks, and inflation or deflation affect our results of operations.
🔒
🟡 Modified
•We and our products face intense competition, including from multinational pharmaceutical companies, biotechnology companies, and lower-cost generic and biosimilar manufacturers, and such competition could have a material adverse effect on our business.
🔒
🟡 Modified
•Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected.
🔒
🟡 Modified
•We derive a significant percentage of our total revenue from relatively few products and sell our products through consolidated supply chain entities, which subjects us to various risks.
🔒
🟡 Modified
•Regulatory compliance problems could be damaging to the company.
🔒
🟡 Modified
•Reliance on third-party relationships and outsourcing arrangements could adversely affect our business.
🔒